Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Rare Tumour × Irinotecan × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 329 Rectal Neoplasms 131 Colonic Neoplasms 130 Stomach Neoplasms 94 Pancreatic Neoplasms 93 Neoplasm Metastasis 72 Neoplasms 62 Esophageal Neoplasms 53 Small Cell Lung Carcinoma 38 Neuroblastoma 35 Lung Neoplasms 35 Glioblastoma 35 Carcinoma, Non-Small-Cell Lung 31 Esophageal Squamous Cell Carcinoma 29 Brain Neoplasms 28 Unspecified Adult Solid Tumor, Protocol Specific 26 Breast Neoplasms 26 Glioma 25 Adenocarcinoma Of Esophagus 25 Sarcoma 21 Gliosarcoma 20 Central Nervous System Neoplasms 20 Rhabdomyosarcoma 18 Astrocytoma 17 Sarcoma, Ewing 16 Gastrointestinal Neoplasms 15 Oligodendroglioma 13 Adenocarcinoma 13 Recurrence 12 Medulloblastoma 11

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡